Ciruelos, Eva
García-Sáenz, Jose Ángel
Gavilá, Joaquín
Martín, Miguel
Rodríguez, César A.
Rodríguez-Lescure, Álvaro http://orcid.org/0000-0002-6823-5290
Funding for this research was provided by:
Daiichi Sankyo and AstraZeneca (Funding of the writing of the manuscript)
Article History
Received: 9 October 2023
Accepted: 4 January 2024
First Online: 9 February 2024
Declarations
:
: EC: consulting fees (e.g., advisory boards) from Lilly, Novartis, Pfizer, Roche, AstraZeneca, Daiichi Sankyo, MSD, and Gilead. JG-S: consultative and advisory services from Seagen, AstraZeneca, Daiichi Sankyo, Novartis, Gilead, Menarini; consultancy/speaker fees from Celgene, Eli Lilly, Eisai, MSD, Exact Sciences, Tecnofarma, and Nolver (Adium); institution research funding from AstraZeneca; and travel support from Novartis, AstraZeneca, and Pfizer. JG: invited speaker for Novartis, Pfizer, Lilly, Roche, AstraZeneca, Daiichi Sankyo, and MSD; and advisory role and speaker for Novartis, Seagen, Roche, AstraZeneca, Daiichi Sankyo, and MSD. MM: grants from Novartis; and personal fees from Roche, AstraZeneca, Pfizer, and Lilly. CAR: advisory role or speaker for Novartis, Lilly, AstraZeneca, Daiichi Sankyo, Seagen, MSD, Pierre Fabre, Pfizer, Veracyte, Roche, and Eisai. AR-L: consultant or advisor fees from Roche, Pfizer, Novartis, Lilly, AstraZeneca, Daiichi Sankyo, Gilead, Pierre Fabre, MSD, Organon, and Seagen; research funding for his institution from Roche, Novartis, Pfizer, Lilly, AstraZeneca, MSD, Radius, Zymeworks, Gilead, GEICAM, and Sanofi; speaker’s fees from Roche, Pfizer, Novartis, Lilly, AstraZeneca, Gilead, Daiichi Sankyo, Eisai, MSD, and Seagen; and travel grants from Roche, Pfizer, and Novartis.
: This article does not contain any studies with human participants or animals performed by any of the authors.